Bank of Montreal’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.08M | Buy |
31,003
+7,368
| +31% | +$978K | ﹤0.01% | 1386 |
|
|
2025
Q4 | $3.35M | Sell |
23,635
-80
| -0.3% | -$11.6K | ﹤0.01% | 1481 |
|
|
2025
Q3 | $3.33M | Sell |
23,715
-6,808
| -22% | -$922K | ﹤0.01% | 1466 |
|
|
2025
Q2 | $3.84M | Sell |
30,523
-2,182
| -7% | -$250K | ﹤0.01% | 1353 |
|
|
2025
Q1 | $3.62M | Sell |
32,705
-2,389
| -7% | -$303K | ﹤0.01% | 1289 |
|
|
2024
Q4 | $4.79M | Sell |
35,094
-20,150
| -36% | -$2.49M | ﹤0.01% | 1233 |
|
|
2024
Q3 | $6.36M | Buy |
55,244
+15,893
| +40% | +$2.18M | ﹤0.01% | 1217 |
|
|
2024
Q2 | $5.42M | Buy |
39,351
+2,102
| +6% | +$288K | ﹤0.01% | 1231 |
|
|
2024
Q1 | $5.14M | Sell |
37,249
-8,414
| -18% | -$1.15M | ﹤0.01% | 1212 |
|
|
2023
Q4 | $6.08M | Sell |
45,663
-108,729
| -70% | -$12.5M | ﹤0.01% | 1204 |
|
|
2023
Q3 | $17.6M | Sell |
154,392
-127,769
| -45% | -$13.5M | 0.01% | 760 |
|
|
2023
Q2 | $27.7M | Buy |
282,161
+215,023
| +320% | +$21M | 0.01% | 615 |
|
|
2023
Q1 | $6.81M | Buy |
67,138
+8,038
| +14% | +$836K | ﹤0.01% | 1098 |
|
|
2022
Q4 | $7.1M | Buy |
59,100
+63
| +0.1% | +$7.38K | ﹤0.01% | 1126 |
|
|
2022
Q3 | $6.3K | Buy |
59,037
+48,143
| +442% | +$4.88M | ﹤0.01% | 1233 |
|
|
2022
Q2 | $1.07K | Sell |
10,894
-71,849
| -87% | -$6.63M | ﹤0.01% | 2261 |
|
|
2022
Q1 | $7.67M | Sell |
82,743
-28,078
| -25% | -$2.38M | ﹤0.01% | 1268 |
|
|
2021
Q4 | $9.4M | Sell |
110,821
-636,419
| -85% | -$58.5M | 0.01% | 975 |
|
|
2021
Q3 | $71.1M | Buy |
747,240
+385,781
| +107% | +$36.4M | 0.03% | 443 |
|
|
2021
Q2 | $36.2M | Buy |
361,459
+8,024
| +2% | +$769K | 0.02% | 627 |
|
|
2021
Q1 | $32.8M | Buy |
353,435
+84,197
| +31% | +$8.83M | 0.02% | 529 |
|
|
2020
Q4 | $29.7M | Buy |
269,238
+141,351
| +111% | +$13.7M | 0.02% | 565 |
|
|
2020
Q3 | $12.4M | Sell |
127,887
-14,221
| -10% | -$1.65M | 0.01% | 759 |
|
|
2020
Q2 | $18.7M | Buy |
142,108
+107,945
| +316% | +$11.9M | 0.02% | 610 |
|
|
2020
Q1 | $2.95M | Sell |
34,163
-342
| -1% | -$33.5K | ﹤0.01% | 1242 |
|
|
2019
Q4 | $3.71M | Sell |
34,505
-29,694
| -46% | -$3.11M | ﹤0.01% | 1528 |
|
|
2019
Q3 | $5.79M | Buy |
64,199
+8,227
| +15% | +$769K | 0.01% | 1126 |
|
|
2019
Q2 | $4.73M | Buy |
55,972
+35,360
| +172% | +$2.9M | ﹤0.01% | 1230 |
|
|
2019
Q1 | $1.82M | Sell |
20,612
-43,249
| -68% | -$3.61M | ﹤0.01% | 1731 |
|
|
2018
Q4 | $4.56M | Buy |
63,861
+991
| +2% | +$94.9K | ﹤0.01% | 1115 |
|
|
2018
Q3 | $7.73M | Buy |
62,870
+32,855
| +109% | +$3.73M | 0.01% | 997 |
|
|
2018
Q2 | $2.95M | Buy |
30,015
+186
| +0.6% | +$16.6K | ﹤0.01% | 1433 |
|
|
2018
Q1 | $2.47M | Buy |
29,829
+19,062
| +177% | +$1.61M | ﹤0.01% | 1474 |
|
|
2017
Q4 | $835K | Buy |
10,767
+8,837
| +458% | +$603K | ﹤0.01% | 2039 |
|
|
2017
Q3 | $119K | Buy |
1,930
+883
| +84% | +$46.6K | ﹤0.01% | 2913 |
|
|
2017
Q2 | $48K | Sell |
1,047
-71
| -6% | -$3.44K | ﹤0.01% | 3232 |
|
|
2017
Q1 | $48K | Sell |
1,118
-323
| -22% | -$13.8K | ﹤0.01% | 3094 |
|
|
2016
Q4 | $67K | Buy |
1,441
+721
| +100% | +$32.6K | ﹤0.01% | 3009 |
|
|
2016
Q3 | $36K | Hold |
720
| – | – | ﹤0.01% | 3150 |
|
|
2016
Q2 | $33K | Sell |
720
-814
| -53% | -$37.5K | ﹤0.01% | 3193 |
|
|
2016
Q1 | $61K | Buy |
1,534
+79
| +5% | +$3.13K | ﹤0.01% | 2977 |
|
|
2015
Q4 | $82K | Buy |
1,455
+592
| +69% | +$30.1K | ﹤0.01% | 2851 |
|
|
2015
Q3 | $34K | Buy |
+863
| New | +$41.7K | ﹤0.01% | 3055 |
|
|
2015
Q2 | – | Sell |
-447,200
| Closed | -$17.8M | – | 4052 |
|
|
2015
Q1 | $17.8M | Buy |
+447,200
| New | +$16M | 0.02% | 558 |
|
|
2014
Q3 | – | Sell |
-1,860
| Closed | -$28K | – | 4266 |
|
|
2014
Q2 | $28K | Buy |
+1,860
| New | +$26.2K | ﹤0.01% | 3447 |
|
Other funds holding NBIX
VPM
VCM
Bank of Montreal's NBIX Position: Q1 2026 in Review
Bank of Montreal increased its Neurocrine Biosciences (NBIX) stake by 31% in Q1 2026, buying an estimated $978K and bringing the position to 31,003 shares worth $4.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1386.
Bank of Montreal first reported a position in NBIX in Q2 2014 and has held it in 45 quarters since. The position peaked at $71.1M in Q3 2021. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Bank of Montreal held 31,003 shares of Neurocrine Biosciences worth $4.08M as of Q1 2026.
- Bank of Montreal bought 7,368 Neurocrine Biosciences shares in Q1 2026, an estimated $978K.
- Neurocrine Biosciences made up ﹤0.01% of Bank of Montreal's portfolio in Q1 2026, its #1386 holding.
- Bank of Montreal first reported a position in Neurocrine Biosciences in Q2 2014 and has held it in 45 quarters since.
- Bank of Montreal's Neurocrine Biosciences position peaked at $71.1M in Q3 2021.
- 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Bank of Montreal's 13F filing for Q1 2026, filed 13 May 2026.